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UK: 7%, 4%/6%, 16%/79%/2%/4%. Within each country,
burden of type 2 diabetes tended to increase with age among
diabetic individuals (all-age, 18–24, 25–34, 35–44, 45–54,
55–64, 65–69 yrs: % pts): Italy: 61%, 17%, 16%, 31%, 66%,
79%, 61%; France: 63%, 7%, 19%, 46%, 61%, 73%,
76%; Spain: 66%, 18%, 16%, 44%, 75%, 68%, 93%; UK:
79%, 10%, 34%, 64%, 84%, 89%, 93%; Germany: 81%, 22%,
27%, 60%, 82%, 91%, 85%; The Netherlands: 84%, 50%,
50%, 71%, 86%, 89%, 92%. Type of treatment observed
among type 1/type 2 diabetics varied across the countries (not
mutually exclusive: % using Dietary restrictions/exercise, Oral-
therapy/oral-antidiabetics, Insulin therapy): The Netherlands:
type 1—16%, 4%, 92%, type 2—39%, 63%, 22%; UK: type
1—19%, 13%, 81%, type 2—39%, 62%, 16%; Spain:
type 1—33%, 13%, 73%, type 2—57%, 61%, 17%; Germany:
type 1—19%, 17%, 79%, type 2—61%, 54%, 25%;
France: type 1—52%, 44%, 35%, type 2—66%, 78%, 16%;
Italy: type 1—58%, 27%, 44%, type 2—79%, 77%,
14%. Among those using medications to manage diabetes, pre-
scription medicines predominated (range: 74% (Spain) to 86%
(The Netherlands)); use of OTC-products/complementary-
therapy was rare (<1%–3%), and so as herbal-therapy (<1%–
4%, except in Spain (12%)). CONCLUSIONS: Diabetes disease
burden appear to be substantial in European nations studied,
with type 2 diabetes burden increasing with age. The reported
treatment patterns varied dramatically. With the aging European
population, appropriate interventions, outcome evaluations and
cost-effective diabetes management strategies are warranted to
alleviate this burden.
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OBJECTIVES: This study aimed to model the increase in
osteoporosis-related fractures and the associated costs related
with aging and testosterone deﬁciency (TD) in the male popu-
lation above 65 years in the Brazilian Private Health System
(PHS). METHODS: Population-based prospective cohorts
established age-speciﬁc annual incidence rates of testosterone
deﬁciency and the prevalence of osteoporosis in men. Based on
these estimates, projections for the number of cases of men
with testosterone deﬁciency, osteoporosis and fractures in the
Brazilian male population above 65 years were computed. The
national costs associated with hip fractures have been previ-
ously recorded as R$ 24,051 (US$14,402) per event. RESULTS:
Among 1,164,379 male individuals above 65 years under the
Brazilian PHS, 27,130 new cases of TD would be expected in
one year. Considering an osteoporosis incidence of 6% and
12.3% for men with normal and deﬁcient testosterone, respec-
tively, 1709 new cases of osteoporosis attributed to TD would
be expected. This would result in an annual absolute increase
of 0.16% in non-vertebral fracture incidence in men between
65–69 years; 0.24% between 70–74 years; 0.32% between
75–79 years and 0.40% above 80 years. Each of these absolute
increases represents a 105% relative increase in the incidence of
non-vertebral fractures between men with TD relative to men
without TD. Seventy-one new non-vertebral fractures and 13
new cases of hip fractures would be expected, resulting in
incremental costs of R$318,002 (US$190,420) for the Brazilian
PHS. CONCLUSIONS: Male aging is associated with gradual
decrease in circulating testosterone, which may be detrimental
to bone. This model suggests that, for the Brazilian male popu-
lation above 65 years, testosterone deﬁciency is associated with
a signiﬁcant increase in new cases of osteoporosis-related frac-
tures in one year. Diagnosis and proper treatment of this con-
dition could have a favorable impact in the prevention of this
costly complication.
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OBJECTIVES: Diabetes patients’ management is complex and
requires that many issues, beyond glycemic control, be
addressed. Management of lipid proﬁle is a crucial component of
cardiovascular (CV) risk reduction in diabetic population. We
assessed the characteristics of dyslipidemia among an adult type
2 diabetes mellitus (T2DM) population that added either sulpho-
nylurea (SU) or a PPARg agonist to previous metformin (MF)
therapy in Spain. METHODS: A retrospective clinical chart
review and patient survey during physician visits (June 2006-
February 2007) was conducted in Spain. Patients were aged 30
years at time of T2DM diagnosis and added SU or a PPARg
agonist to previous MF between 2001 and 2006. Patients with
gestational diabetes or T1DM were excluded. For the present
analysis patients with missing values for LDL-c, HDL-c or trig-
lycerides (TGs) were excluded. Individual patient lipid proﬁles
were compared with the recommended lipid targets for diabetic
patients by the latest ADA consensus. RESULTS: A total of 493
patients were recruited, and 338 included in this analysis.
Average age was 63.1 (SD 10.6) years, 46.7% were female, and
mean time from diabetes diagnosis was 8.6 (SD 5.3). The lipid
parameter most frequently not at target was LDL-c (79.6%),
followed by TGs (42.9%) and HDL-c (37.6%). 17.5% of
patients had the three lipid parameters out of goal, and 31.4%
had two of them not at target. Out of the 338 patients only 20 (a
6% approx.) presented all three lipid parameters at the recom-
mended level. CONCLUSIONS: diabetic patients that start oral
combination therapy with either MF+SU or MF + a PPARg
agonist, very frequently have their lipid parameters not at rec-
ommended level. A greater focus is required to comprehensively
manage their lipid proﬁle, and reduce the cardiovascular risk
associated with it.
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OBJECTIVES: Diabetic patients are at CHD greater risk than
the general population. Therefore these patients will beneﬁt
from optimal care based on CHD risk evaluation. We assessed
the potential impact of risk factors (RF) management on the
cardiovascular (CV) risk among T2DM population.
METHODS: A retrospective cohort study was conducted in
Spain (2006–2007). Patients were aged 30 years at time of
T2DM diagnosis and had added sulphonylurea or PPARg
agonist to previous metformin. Patient RFs were assessed for
attainment of guideline-deﬁned optimal values. The data for
these patients correspond to their last available measurements
before add-on therapy. Five-year CV risk was estimated with a
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